Roche Gains FDA sBLA Acceptance for Lunsumio VELO Plus Polivy in Relapsed or Refractory LBCL

A supplemental Biologics License Application (sBLA) acceptance by the FDA signals that Roche's subcutaneous reformulation of mosunetuzumab (Lunsumio VELO) has cleared the agency's threshold for substantive review, placing QA and regulatory teams at sites handling biologic reformulations on notice ahead of a potential label change. The FDA has set a target decision date of 9 February 2027.

The filing is anchored in data from the phase III SUNMO study, which evaluated Lunsumio VELO in combination with Polivy (polatuzumab vedotin) against R-GemOx in adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior systemic therapy. At a median follow-up of 23.2 months, the combination produced a 59% reduction in risk of disease progression or death versus R-GemOx (HR 0.41; 95% CI: 0.28–0.61; p<0.0001), with median progression-free survival of 11.5 months compared to 3.8 months for the comparator arm.

For regulatory affairs leads, the sBLA pathway here reflects a delivery-format change, intravenous to subcutaneous, rather than a new molecular entity, a distinction that shapes the data package requirements under 21 CFR Part 601 and ICH Q8 comparability principles. The cytokine release syndrome (CRS) profile reported in SUNMO is relevant to labeling strategy: CRS occurred in approximately one in four patients in the Lunsumio VELO plus Polivy arm, with fewer than 5% experiencing Grade 2 or 3 events, a profile consistent with the individual agents' known safety data.

The subcutaneous formulation carries direct operational implications. An outpatient-ready regimen reduces the site infrastructure burden typically associated with intravenous biologic administration, potentially expanding the treatment-eligible population to community oncology settings where the majority of US LBCL patients are managed. Updated SUNMO data presented at ASCO and the European Hematology Association Congress in 2026 showed sustained PFS benefit with longer follow-up and no new safety signals, reinforcing the data package submitted to the agency.

LBCL, predominantly diffuse large B-cell lymphoma, accounts for more than 18,000 new US diagnoses annually; roughly 40% of patients relapse or develop refractory disease, at which point salvage options are limited and time-sensitive. Manufacturing and quality teams preparing for a potential approval should begin assessing comparability documentation, cold-chain requirements for the subcutaneous formulation, and any site-specific process validation updates required under ICH Q10 quality system frameworks.

The February 2027 PDUFA date gives supply chain and regulatory operations approximately eight months to align distribution readiness with a potential label expansion.

Source: Roche via GlobeNewswire, 18 June 2026.